{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "End of Study Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_2",
        "name": "Zinc Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_3",
        "name": "Tetrathiomolybdate Washout Period",
        "type": "Before",
        "unit": "years",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_4",
        "name": "Experimental Therapy Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening"
      },
      {
        "id": "timing_5",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_6",
        "name": "Non-Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7
      },
      {
        "id": "timing_7",
        "name": "Alcohol Abstinence Prior to Dosing",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 48,
        "relativeTo": "First Dose",
        "windowLower": -48,
        "windowUpper": 0
      },
      {
        "id": "timing_8",
        "name": "Post-Dose Fasting",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 2,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_9",
        "name": "Outpatient Period Extension",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14,
        "windowLower": 0,
        "windowUpper": 14
      },
      {
        "id": "timing_10",
        "name": "Chelator Discontinuation",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_11",
        "name": "Pregnancy Test Frequency",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit"
      },
      {
        "id": "timing_12",
        "name": "CRU Re-admission",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "relativeTo": "First Dose",
        "windowLower": 22,
        "windowUpper": 23
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "SRC Safety Review for Titration",
        "instanceType": "Condition",
        "description": "Safety Review Committee must review available safety data before dose titration.",
        "text": "SRC will review available safety data through Day 23 for each participant."
      },
      {
        "id": "cond_2",
        "name": "Dose Modification for Neutropenia",
        "instanceType": "Condition",
        "description": "Criteria for dose modification due to low neutrophil count.",
        "text": "Neutrophils > 30% decrease from baseline and below reference range at baseline."
      },
      {
        "id": "cond_3",
        "name": "Dose Modification for Liver Injury",
        "instanceType": "Condition",
        "description": "Criteria for dose modification due to potential liver injury.",
        "text": "Bilirubin > 2x ULN accompanied by ALT > 3x ULN."
      },
      {
        "id": "cond_4",
        "name": "Dose Modification for Neurologic Worsening",
        "instanceType": "Condition",
        "description": "Criteria for dose modification due to neurologic worsening.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment."
      },
      {
        "id": "cond_5",
        "name": "Dose Modification for Psychiatric Worsening",
        "instanceType": "Condition",
        "description": "Criteria for dose modification due to psychiatric worsening.",
        "text": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis."
      },
      {
        "id": "cond_6",
        "name": "Intervention Discontinuation Criteria",
        "instanceType": "Condition",
        "description": "Conditions requiring permanent discontinuation of the study intervention.",
        "text": "Serious hypersensitivity reaction; Severe uncontrolled infection; Use of disallowed medication; Pregnancy or planned pregnancy."
      },
      {
        "id": "cond_7",
        "name": "Rechallenge Limit",
        "instanceType": "Condition",
        "description": "The maximum number of times a participant can be rechallenged with the study drug after a dose interruption.",
        "text": "A maximum of 3 rechallenges will be allowed."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Enrollment",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_screening",
        "toElementId": "epoch_run_in",
        "text": "Participants who sign ICF, are eligible, and are registered on Day -7 are considered enrolled."
      },
      {
        "id": "trans_2",
        "name": "Dose Titration to 30mg",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_30mg",
        "text": "Participants will be administered ALXN1840 at 15 mg/day and increase to 30 mg/day on Day 29, pending SRC safety review."
      },
      {
        "id": "trans_3",
        "name": "Dose Reduction for Neutropenia",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If neutrophils > 30% decrease from baseline and below reference range, reduce dose to previous dose level or to 15 mg QOD if on 15 mg QD."
      },
      {
        "id": "trans_4",
        "name": "Dose Interruption for Liver Injury",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Bilirubin > 2x ULN and ALT > 3x ULN, temporarily interrupt dosing."
      },
      {
        "id": "trans_5",
        "name": "Intervention Discontinuation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "fromElementId": "epoch_treatment",
        "toElementId": "epoch_safety_followup",
        "text": "Participants must be considered for discontinuation from study intervention for reasons including serious hypersensitivity, severe infection, disallowed medication, or pregnancy."
      },
      {
        "id": "trans_6",
        "name": "Post-Study Therapy Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_treatment",
        "toElementId": "epoch_post_study",
        "text": "Following completion of the study (ie, Day 40), participants will transition to prior therapy, other standard of care, or request continuation of ALXN1840."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure (EOS Visit on Day 54 +/- 2 days)."
      },
      {
        "id": "exit_2",
        "name": "Participant Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discretionary Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered lost to follow-up if they repeatedly fail to return for visits and are unable to be contacted after documented attempts (3 calls, 1 certified letter)."
      },
      {
        "id": "exit_5",
        "name": "Sponsor Termination",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion reserves the right to close the study site or terminate the study at any time."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Titration Decision",
        "timepointId": "Day 29",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point on Day 29 to titrate dose from 15 mg/day to 30 mg/day, based on SRC safety review of data through Day 23.",
        "conditionIds": [
          "cond_1"
        ]
      },
      {
        "id": "dec_2",
        "name": "Ongoing Dose Modification Decision",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing decisions to modify, interrupt, or reduce dose based on safety monitoring for hematology, liver function, neurologic, and psychiatric events.",
        "conditionIds": [
          "cond_2",
          "cond_3",
          "cond_4",
          "cond_5"
        ]
      },
      {
        "id": "dec_3",
        "name": "Intervention Discontinuation Decision",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to permanently discontinue a participant from the study intervention based on specific safety criteria.",
        "conditionIds": [
          "cond_6"
        ]
      }
    ],
    "summary": {
      "timingCount": 12,
      "conditionCount": 7,
      "transitionRuleCount": 6,
      "exitCount": 5
    }
  }
}